[The modification of high density lipoproteins by malondialdehyde changes their interaction with J774 macrophages and decreases cholesterol cell efflux].
The treatment of HDL3 with malondialdehyde (MDA) results in an increase of the electrophoretic mobility of the particle and in aggregation of the apolipoprotein AI. The binding of MDA-treated-HDL3 to murine macrophages J774 is decreased, as compared to native HDL3. The cholesterol efflux is also markedly reduced. In view of the fact that MDA is produced following plaquette aggregation or oxidative stress, the eventual existence of MDA-modified-HOL in vivo might accelerate the appearance of atherosclerotic lesions by reducing cellular cholesterol efflux.
Salmon
S
S
Laboratoire de Chimie-Biologique, Faculté de Médecine Saint-Antoine, Paris.
Mazière
J C
JC
Mazière
C
C
Auclair
M
M
Santus
R
R
Polonovski
J
J
D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D002784:Cholesterol / Q000378:metabolism*; D004347:Drug Interactions; D008075:Lipoproteins, HDL / Q000494:pharmacology*; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism*; D008315:Malondialdehyde / Q000494:pharmacology*; D051379:Mice
D008075:Lipoproteins, HDL; D008315:Malondialdehyde; D002784:Cholesterol
La modification des lipoprotéines de haute densité par le malondialdéhyde altère leur interaction avec les macrophages J774 et diminue l'efflux cellulaire du cholestérol.